Although PRLR is highly expressed by many tumors across breast cancer subtypes, data from small clinical trials inhibiting PRL action are difficult to interpret, and studies of xenografts, particularly of breast cancer cell lines, are conflicting. Here, PRLR is linked to breast carcinoma.